Finally, studies often do not separately investigate subclasses of diuretics (thiazides/K-sparing/loop) and CCBs (dihydropyridine/non-dihydropyridine), despite these subclasses having considerably varying clinical indications and mechanisms of action.8, 9, 10,16 Recent studies suggest that specifically angiotensin-II-receptors type 2 and 4 (Ang-II) stimulating AHM-subclasses (ARBs, dihydropyridine CCBs, thiazides), lower dementia risk compared to Ang-II-inhibiting subclasses (angiotensin-converting enzyme inhibitors [ACEi], non-dihydropyridine CCBs, beta blockers).14 This evidence concerns the gene ACE and dementia.